Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Cost-Effectiveness of Thrombolysis within 4.5 Hours of Acute Ischemic Stroke in China
First author：Yuesong Pan,Qidong Chen
Corresponding author：Yongjun Wang,Yilong Wang
essential_information
- Person in charge：Yuesong Pan,Qidong Chen
- Data Sources： TIMS-CHINA
- Number of papers：TIMS-CHINA20150140
- Published time：2014-10-01
2014-10-01
Published articles
Journal：PLOS ONE
Publication type: Original Contributions
IF(IF): 3.24
PMID: 25329637 Link To Pubmed Full text Download
Background And Purpose
Previous economic studies conducted in developed countries showed intravenous tissue-type plasminogen activator (tPA) is cost-effective for acute ischemic stroke. The present study aimed to determine the cost-effectiveness of tPA treatment in China, the largest developing country.
Method
A combination of decision tree and Markov model was developed to determine the cost-effectiveness of tPA treatment versus non-tPA treatment within 4.5 hours after stroke onset. Outcomes and costs data were derived from the database of Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China) study. Efficacy data were derived from a pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Costs and quality-adjusted life-years (QALYs) were compared in both short term (2 years) and long term (30 years). One-way and probabilistic sensitivity analyses were performed to test the robustness of the results.
Conclusion
Intravenous tPA treatment within 4.5 hours is highly cost-effective for acute ischemic strokes in China.
Main results
A combination of decision tree and Markov model was developed to determine the cost-effectiveness of tPA treatment versus non-tPA treatment within 4.5 hours after stroke onset. Outcomes and costs data were derived from the database of Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China) study. Efficacy data were derived from a pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Costs and quality-adjusted life-years (QALYs) were compared in both short term (2 years) and long term (30 years). One-way and probabilistic sensitivity analyses were performed to test the robustness of the results.